Interest of the Smartphone Application "MonCœur" in the Follow-up of Patients With Heart Failure (APPLIMONCOEUR)

French Cardiology Society

Status

Terminated

Conditions

Heart Decompensation

Heart Failure

Treatments

Device: APPLI

Study type

Interventional

Funder types

Other

Identifiers

NCT04198779

2019-01

Details and patient eligibility

About

Heart failure is a chronic disease that requires careful monitoring and therapeutic education. Smartphones have made their appearance in patients lives and allow close contact with them. The possibility of using a digital application dedicated to patients with heart failure concerning the symptoms to be monitored, treatments, diet, appointments, physical activity could improve the monitoring and the prognosis of patients following their hospitalization.

Full description

The aim of this study is to demonstrate that the use of a special application dedicated to the monitoring of heart failures disease has a favorable impact on the occurrence of readmissions and, ultimately, cardiovascular mortality. The aim of this study is also to demonstrate that the use of this "MonCœur" application improves symptoms, quality of life, treatment compliance, diet compliance, and physical activity in patient with heart failure disease.

Enrollment

125 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patient hospitalized for acute or decompensated heart failure
Patient with a smartphone and able to use a digital application
Beneficiary of a social protection scheme
Patients benefiting from a telemedicine program can be included

Exclusion criteria

Acute coronary syndrome during ongoing hospitalization.
Acute myocarditis, constrictive pericarditis, acute endocarditis during ongoing hospitalization.
Isolated right heart failure of respiratory origin.
Existence of a cause considered rapidly reversible to acute heart failure: tachyarrhythmia, excessive bradycardia, acute anemia, acute renal failure, malignant hypertension, overdose or cardiotoxic drug intoxication.
Indication of cardiac surgery scheduled within 3 months after hospitalization, patients with Tavi or MItraclip expected within 3 months
Extracardiac disease with short-term prognosis (progressive neoplasia).
Refusal or incapacitation of language or psychic to sign informed consent
Patients participating in an other biomedical research can not participate in this study for the first 6 months, not to interfere with the consultation process of the study.
Pregnant or lactating women can't participate in the study.